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INTRODUCTION
Although cancer remains the current leading cause of death by
disease in children under 15 years, recent advances in pediatric
cancer treatment have significantly increased long-term survival
rates up to 80%.[1] However, potentially serious treatment
complications as well as sensory deficits such as hearing loss after
chemotherapy, optic atrophy from cranial radiation therapy, or
increased intracranial pressure are recognized in the literature.[2]
Patients with brain tumors (BT) are especially prone to neuro-
cognitive sequelae, which may result from the tumor itself or
potentially from various therapeutic interventions such as surgery,
radio- and chemotherapy.[1] Long-term follow-up studies of
children with BT have demonstrated a range of cognitive deficits,
affecting intelligence, memory, attention, executive function, and
academic performance.[e.g., 3,4] Poor academic achievement is
likely to negatively influence the patients’ chances of reaching
subsequent vocational and economic goals.[5]
However, cognitive impairment caused by a tumor can be highly
variable[6] and some deficits might not become evident until
several years after treatment.[7] Shortman and colleagues[8]
reported that pediatric patients with BT showed significantly
reduced performance on measures of processing speed, memory,
and attention when compared with healthy age-matched children
after surgery. The adverse effects of radiation on the developing
brain have long been recognized.[9,10] Impairment of learning and
memory is among the most common sequelae of radiotherapy.[11]
Chemotherapy is usually less neurotoxic than radiation, but can also
negatively affect neurocognitive functions including attention,
processing speed, executive functioning, and memory.[12,13]
The majority of pediatric brain tumor studies have focused on
the post-treatment cognitive deficits in children with brain tumors.
Presurgery assessments are often not undertaken due to the
associated practical difficulties.[8] Therefore, literature on the
pre-treatment neuropsychological status of these patients is scarce.
Lazareff and Castro-Sierra[14] reported that children with
cerebellar tumors, who were tested 3–4 days prior to surgery,
performed worse on measures of auditory memory than the age-
matched healthy control group, which consisted of patients’
siblings, while their visual memory performance was comparable.
Varela and colleagues[15] investigated the cognitive profile of
posterior cerebellar and fourth ventricle tumors in 24 children
(range 4–15 years) before any therapeutic intervention and
compared their performance with age-matched children treated in
the same hospital for abdominal ailments. No group differences
were found in measures of IQ, visual perception, visual memory,
and visuomotor integration skills. Attention, verbal learning, and
memory were not measured in this study.
Di Rocco and colleagues[16] investigated cognitive functioning
in children with medulloblastoma and astrocytoma before surgery
(41 children, age range 2–6 years). They showed that in some
children attention and executive problems were already present
before treatment. Similarly, Iuvone and colleagues[17] reported
that prior to any medical treatment, almost 50% of 83 children (age
range 7 months to 16 years) with various BT showed difficulties in
some cognitive domains such as attention, verbal working memory,
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Background. Survivors of brain tumors have a high risk for a wide
range of cognitive problems. These dysfunctions are caused by the
lesion itself and its surgical removal, as well as subsequent treatments
(chemo- and/or radiation therapy). Multiple recent studies have
indicated that children with brain tumors (BT) might already exhibit
cognitive problems at diagnosis, i.e., before the start of any medical
treatment. The aimof the present studywas to investigate the baseline
neuropsychological profile in childrenwith BT compared to children
with an oncological diagnosis not involving the central nervous
system (CNS). Methods. Twenty children with BT and 27 children
with an oncological disease without involvement of the CNS (age
range: 6.1–16.9 years) were evaluated with an extensive battery of
neuropsychological tests tailored to the patient’s age. Furthermore,
the child and his/her parent(s) completed self-report questionnaires
about emotional functioning and quality of life. In both groups, tests
were administered before any therapeutic intervention such as
surgery, chemotherapy, or irradiation.Groupswere comparablewith
regard to age, gender, and socioeconomic status. Results. Compared
to the control group, patients with BTs performed significantly worse
in tests of working memory, verbal memory, and attention (effect
sizes between 0.28 and 0.47). In contrast, the areas of perceptual
reasoning, processing speed, and verbal comprehension were
preserved at the time of measurement. Conclusion. Our results
highlight the need for cognitive interventions early in the treatment
process in order to minimize or prevent academic difficulties as
patients return to school. © 2015 The Authors. Pediatric Blood &
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planning tasks, and visual-motor integration. Twelve percent of
these children reached IQ values below the normal range, while 6%
displayed values in the range of mental retardation. Stargatt and
colleagues[18] showed that children aged 4–16 with posterior fossa
tumors showed deficits in sustained attention and processing speed
even before surgery, and that these deficits increased over time
during the three subsequent years after surgery and cranial
radiation. Even though these three studies[16–18] showed that
impairments of some basic functions like attention and memory can
be detected at diagnosis, none of the studies included a control
group of children newly diagnosed with a non-CNS oncological
disease (CG).
In summary, a number of empirical studies indicate that
specific functional deficits in children with BT can be measured
before surgical or subsequent treatments commence. Cognitive
functions like memory and attention, which are key functions for
acquiring new information, seem to be affected most.[13] The CNS
is constantly developing in childhood, and therefore interruption of
this process by tumor infiltration can profoundly impair the creation
of new neural networks and in consequence, cognitive develop-
ment. The present study investigated the cognitive performance of
children with newly diagnosed BTs in comparison to age-matched
patients with other oncological diseases without involvement of
the CNS. Since anxiety, apprehension, and physical discomfort are
likely to affect cognitive functioning, it would be relevant to
compare the performance of both groups of children. Children in
our oncological CG are, due to their illness, exposed to a similar
level of emotional and physical distress, but are not expected to
show systematic cognitive problems.
Given that others have already reported on cognitive problems
in children with BT at diagnosis,[16–18] we hypothesized that
children with BT would perform poorer in tests of attention and
memory as compared to CG patients. Furthermore, we postulated
that the number of test scorings below one standard deviation or
more below the age-adjusted normative mean would be higher in
the BT sample than in the CG.
METHODS
In January 2010, a neuropsychological care program was
implemented in the medical treatment routine at the Department of
Pediatric Hematology/Oncology of the Children’s University
Hospital in Bern. All children aged 3–18 years suffering from an
oncological disease, with or without involvement of the CNS, have
been included in this clinical routine. Patients usually complete
three standardized cognitive test batteries tailored to their age to
monitor the cognitive development: (1) at diagnosis (baseline
assessment), (2) immediately after the intensive medical treatment
phase (i.e., in children with acute lymphoblastic leukemia at the
beginning of maintenance therapy), and (3) 1 year after the end of
treatment. The test battery for baseline testing covers the
neuropsychological domains at greatest risk following treatments
like radiation and/or chemotherapy, such as attention, working
memory, processing speed, visuospatial abilities, learning, and
memory.[19] If cognitive impairments are detected, cognitive
rehabilitation programs are introduced immediately with the goal to
minimize or even prevent long-term sequelae. For the present
exploratory study, baseline data have been analyzed (2010–2013).
The study has been approved by the Cantonal Ethics Committee of
Bern and followed the principles outlined in “World Medical
Association Declaration of Helsinki: Research involving human
subjects”.
Participants
Of the children who underwent neuropsychological testing
between 2010 and 2013, 47 children met the following inclusion
criteria for the present study: (1) age between 6 and 17 years at
diagnosis to ensure comparability of the age-tailored tests (2) no
premorbid neurological or psychiatric history (3) in the case of
sensory deficits: not interfering with the neuropsychological testing
process (4) at least 13 of 16 cognitive measures completed (see
below), and (5) IQ 70. Children with brain stem tumors were
excluded from neuropsychological assessment due to their poor
prognosis. Patients with tuberous sclerosis complex and neurofi-
bromatosis type one were excluded from the study due to their
potential secondary cognitive problems not directly related to the
tumors. To test for CNS involvement in children with leukemia and
lymphoma, cerebrospinal fluid was tested for malignant cells. In
patients with any neurological abnormality, an MRI was performed
to exclude CNS metastases, which were not found in any of the
children. All tested children had IQs above 70. Therefore, no child
had to be excluded for reasons of intellectual disability. In total, 20
children with BT and 27 control children (CG) with non-CNS
cancer (nine children with acute lymphoblastic leukemia, five
children with Hodgkin lymphoma, four children with osteosarco-
ma, three children with Ewing sarcoma, two children with
lymphoma, two children with acute myeloid leukemia, one child
with rhabdomyosarcoma, and one child with paraganglioma) were
included in the analyses. Diagnostic characteristics of the children
with BT are shown in Table II. Neuropsychological assessments
with children of both groups were performed shortly after diagnosis
and before therapeutic intervention (e.g., surgery, irradiation,
chemotherapy). The demographic characteristics of both groups BT
and CG are presented in Table I. Diagnostic characteristics of the
children with BT are shown in Table II.
Cognitive Assessments and Questionnaires
An extensive cognitive test battery was performed in both
groups of children. All tests were applied in a randomized order.
German versions and German reference norms were used. Because
no German reference norms are available for the CMS Stories, we
used the American norms, which have been verified in many years
of clinical experience. Raw scores were transformed into
standardized IQ scores, index scores, or percentiles adapted to
the age, as dictated by the respective test manuals. Impairment was
defined as a performance of one standard deviation below the
normative mean (i.e., IQ scores/index score<85; percentile<16 or
>84, depending on the respective test). For all neuropsychological
functions of interest (intelligence, verbal learning and memory and
attention), two different tests were administered to increase the
confidence in the validity of the measurement results.
Intelligence. General intelligence (Full Scale IQ, FSIQ) was
assessed using the German version of the “Wechsler Intelligence
scale for children” (WISC).[20,21] Additionally, nonverbal intelli-
gencewas measured using the Test of Nonverbal Intelligence, Third
Edition (TONI-3).[22]
Perceptual reasoning. The perceptual reasoning index score
of the WISC-IV (subtests block design, picture concepts, and
matrix reasoning) was used for perceptual reasoning.
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Verbal comprehension. Verbal comprehension was assessed
using the verbal comprehension index score of the WISC-IV
(subtests similarities, vocabulary, and comprehension).
Working memory. The working memory index score of the
WISC-IV (subtests digit span and letter-number sequencing) was
used for working memory.
Processing speed. Processing speed was measured using the
subtest symbol search of the WISC-IV. This subtest requires less
fine-motor accuracy than the second subtest of the WISC-IV
(coding) and, therefore, allows testing bedside and/or whilewearing
an arm splint on the forearm of the dominant hand.
Verbal learning and memory. Two different verbal tests were
used to assess verbal learning and memory: the German version
of the “Rey Auditory Verbal Learning Test” (RAVLT)[23] and the
subtest “stories” from the Children’s Memory Scale (CMS).[24]
Sustained attention. The computerized “Conner’s Continu-
ous Performance Test” was applied to assess selective and sustained
attention performance (CPT-II version 5),[25] which was measured
in terms of inattention (omission errors) and impulsivity (commis-
sion errors).
Divided attention. The subtest “Divided Attention” of the
computerized “Test of Attention Performance” (TAP version 2.2).
[26] was used to assess divided attention performance. Performance
was measured in terms of inattention (omission errors) and
impulsivity (commission errors) in both visual and auditory tasks.
Questionnaires. Two questionnaires were filled out by the
participating children and their parents: The Strengths and
Difficulties Questionnaire (SDQ)[27] and the quality of life
inventory (Inventar zur Erfassung der Lebensqualit€at von Kindern
und Jugendlichen, ILK).[28]
Procedure
Bedside neuropsychological testingwas performed, the physical
and emotional well-being of the children permitting. Children were
tested in a quiet environment and in a one-to-one setting by a trained
neuropsychologist. Regular breaks were offered.
Statistical Analyses
Due to small sample sizes (20 children with BT, 27 CG
children), non-parametric statistical tests were performed. One-
tailed Mann–Whitney U-tests were used to compare the scores of
each test and subtest between children with BT and CG patients. A
P-value <0.05 was considered a significant effect. Furthermore,
effect sizes of group differences between children with BT and CG
children were calculated. Effect sizes complement inferential
statistics (e.g., P-values) by examining the strength of group
differences independent of sample size. Effect sizes were calculated
with the formula F ¼ Z= ﬃﬃﬃﬃNp .[29] A F-coefficient near 0.5
indicates a large difference between groups (large effect size), a
coefficient near 0.3 indicates amedium effect size, while aF near to
0.1 indicates a small difference between groups (small effect size).
Additionally, it was analyzed if frequencies of impairment (i.e.
performances at least one standard deviation below the normative
mean) were higher in children with BT than CG children by means
of one-tailed Pearson’s x2. All analyses were performed using the
Statistical Package for Social Sciences software for Windows,
version 20 IBM SPSS Statistics (Chicago, Illinois, 2011).
RESULTS
Analyses of Demographic Data
Table I provides the patients’ demographic details. BT and CG
children were comparable in age at assessment (U¼ 344.5,
P¼ 0.11), the distribution of gender (x2(1)¼ 1.95, P¼ 0.24) and
country of origin (x2(5)¼ 5.33, P¼ 0.38). Parental education was
examined as a proxy for socioeconomic status (SES). No
statistically significant differences were found in the professional
status of the parents between children with BTand the CG children
(x2(3)¼ 0.35, P¼ 0.95).
Analyses of Group Differences in Cognitive
Performance
Results are summarized in Table III. Compared to CG children,
children with BT performed significantly worse on measures of
verbal working memory, verbal learning and delayed verbal recall,
recognition of words and stories and attention (commission errors
in sustained and divided attention). There was a tendency for the
WISC Full-Scale-IQ to be lower in BT patients; this however did
not reach statistical significance. No significant differences between
children with BT and CG children in measures of verbal
comprehension (P¼ 0.48), perceptual reasoning (P¼ 0.08), and
in the omission error rates of the sustained (P¼ 0.36) and divided
attention tasks (P¼ 0.12) were found.
Effect sizes (phi-coefficient) revealed a medium-to-large group
difference in processing speed (F¼ 0.35), verbal learning
(F¼ 0.41) and verbal recall of words (F¼ 0.33) and stories
TABLE I. Demographic Characteristics of Brain Tumor Patients and Oncological Control Patients
Group
Variable Measure Brain tumor patients Control patients
Age at diagnosis Months M (SD) 128 (39) 147 (36)
Range 75–186 73–198
Gender Girls n (%) 7 (35.0) 14 (55.6)
Parental educationa Vocational training n (%) 12 (60.0) 14 (51.9)
Secondary school n (%) 1 (5.0) 2 (7.4)
University n (%) 3 (15.0) 5 (18.5)
Not specified n (%) 4 (20.0) 6 (22.2)
M, mean; SD, standard deviation; n, sample size. aParental education serves as a proxy for socioeconomic status (SES).
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TABLE II. Diagnostic Characteristics of the Brain Tumor Patients
No. Histologya Locationb
Brain stem
involvement Symptoms
Symptom
duration
Neurological
deficitsc Ataxia
Oculomotor
palsy
Epileptic
seizures Hydrocephalusd
1 MB IT NO Nausea/vomiting <100 days No No No No Moderate
Headaches
2 ONGe SU No Impaired
hearing
100 days Yes No No No No
Impaired vision
Fine-motor
problems
3 NGCT SM No Nausea/vomiting <100 days Yes No Yes No Marked
4 PA SH No Headaches <100 days Yes Yes No No Marked
Fatigue
Vestibular
disorder
Limping (right)
Back pain
5 NGCT SU No Nausea/vomiting <100 days No No No No No
Headaches
6 PNET SH No Hemiparesis
right
<100 days Yes No No No No
7 ODG SH No Nausea/vomiting <100 days No No No No No
Strabismus
Abdominal pain
8 DNT SH No Headaches <100 days No No No Yes No
Fatigue
9 PA SM No Nausea/vomiting <100 days Yes No No No Marked
Headaches
Impaired vision
Slurred speech
Paraesthesias
10 CP SM No Impaired vision 100 days No No No No No
11 PA IT No Nausea/vomiting <100 days No No No No Moderate
Headaches
Impaired vision
Loss of appetite
12 NGCT SM No Nausea/vomiting <100 days No No no No No
13 PA IT No Nausea/vomiting 100 days Yes Yes no No No
Headaches
14 CPT SH No Nausea/vomiting <100 days No No no No No
Fatigue
15 CS SH No Nausea/vomiting 100 days Yes Yes no No No
Headaches
16 Unknown SM No Headaches 100 days No No no No No
Fatigue
17 MB IT No Nausea/vomiting <100 days No No no No Marked
Headaches
18 GE SM & IT No Nausea/vomiting >100 days No No yes No Marked
Headaches
19 PA SH No Nausea/vomiting <100 days No No no No Marked
Headaches
20 PA SM No Headaches <100 days No No no No No
aHistology: CS, chondrosarcoma; CP, craniopharyngioma; CPT, choroid plexus tumor; DNT, dysembrioplastic neuroepithelial tumor; GE,
germinoma; MB, medulloblastoma; NGCT, nongerminomatous germ cell tumor; ODG, oligodenodroglioma; ONG, optic nerve glioma; PA,
pilocytic astrocytoma. bLocation: IT, infratentorial; SH, supratentorial hemispheric; SM, supratentorial midline; SU, supratentorial unspecified.
cNeurological deficits (manifested as slight motor weakness, clumsiness or impairments in coordination and reflexes): no, absent; yes, mild, not
interfering with daily life. dHydrocephalus: no, absent; moderate, supratentorial convexity spaces not completely effaced; marked, supratentorial
convexity spaces completely effaced. eHistory of neonatal meningitis.
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(F¼ 0.47) as well as in the commission error rates of both
divided (F¼ 0.34) and sustained (F¼ 0.34) attention tasks. All
other effect sizes were small-to-negligible (F¼ 0.05–0.28).
Analyses of Frequencies of Impairment in Cognitive
Performance
Results are shown in Table IV. Children with BT had higher
frequencies of impairment compared to CG children in verbal
learning and recall as well as in the commission error rates of the
divided attention task (more children in the group of BT patients
performed one SD or more below the normative mean as compared
to the children of the CG). There were no differences in frequencies
of impairment in BT and CG children concerning WISC-IV Full-
Scale-IQ and nonverbal IQ, verbal comprehension, perceptual
reasoning, working memory, processing speed, verbal recognition,
the commission error rates in the sustained attention, and the
omission error rates in the sustained and the divided attention tasks.
Four childrenwith BT (20%) showed a performance of one standard
deviation below the normative mean in at least four different
measures (intelligence, working memory, verbal learning, and
attention) compared to one control child (4%).
Analyses of Group Differences in Emotional
Functioning and Quality of Life
All quality of life measures for both patient groups and their
parents were in the range between percentiles 70 and 100,
indicating non-pathological findings. Concerning overall stress
values (measured by SDQ), 95% of the children with BTand 100%
of the CG children indicated average stress levels, while one child in
the BT group revealed an elevated stress level. No group differences
were found in the self-reported questionnaires regarding quality of
life and emotional stress. The quality of life for children of the two
groups (x2(9)¼ 9.00, P¼ 0.44) and their parents (x2(11)¼ 12.71,
P¼ 0.31) and the overall stress score for children (x2(2)¼ 3.73,
P¼ 0.15) and their parents (x2(2)¼ 2.36, P¼ 0.31) were not
significantly different.
DISCUSSION
We investigated a variety of cognitive functions in children with
a newly diagnosed oncological disease with or without CNS
involvement before any major therapeutic intervention. Results
revealed significant differences between the respective groups’
performances in the areas of verbal learning, attention, and working
memory to the disadvantage of children with BT.
In our two different attention tasks (TAP and CPT), children
with BT committed more errors of commission than the CG,
reflecting an impulsive response style. Several studies have
reported attentional deficits in children with BT,[17,18,30,31]
although most findings hint at inattention problems rather than
impulsivity. One explanation for the discrepancy in results may
lie in the different nature of the measures analyzed: Most studies
used a composite measure of attention [e.g., 8,16,32,33] or have
TABLE III. Analyses of Group Differences in Cognitive Performance Between Brain Tumor Patients andOncological Control Patients on
Standardized Measures
Group Test statistics
Brain tumor patients
(n¼ 20)
Control patients
(n¼ 27) Group comparisons
Effect
sizes
Function Measure n Median Range n Median Range Uc P F (Phi)
Fluid intelligence
(TONI-3)a
Nonverbal IQ 17 100 89–130 24 100 83–150 243.5 0.15 0.15
Intelligence (WISC-IV)a Full scale IQ 20 99 77–117 27 108 67–132 339.0 0.051 0.26
Verbal comprehension (WISC
Index)
20 100 81–126 27 101 67–126 272.5 0.48 0.01
Perceptual reasoning (WISC
Index)
20 99 73–121 27 106 73–141 336.5 0.08 0.21
Working memory (WISC Index) 20 95 80–108 27 102 71–141 385.0 0.03* 0.28
Processing speed (WISC Index) 19 97 62–123 26 103 74–134 308.0 0.14 0.16
Verbal learning
(RAVLT)a
Learning (PR trial 1–5) 19 10 1–99 26 70 10–99 371.0 <0.01**(þ) 0.41
Recall (PR trial 7) 19 14 1–99 26 69 1–99 330.5 0.01** 0.33
Recognition (PR) 19 53 1–88 26 75 5–88 312.0 0.03* 0.27
Verbal learninga Immediate recall (PR) 14 50 2–95 22 75 2–99 211.5 0.03* 0.27
(CMS Stories)a Delayed recall (PR) 14 44 2–99 22 80 2–99 218.0 <0.01**(þ) 0.30
Delayed recognition (PR) 14 50 2–84 22 75 16–98 226.0 <0.001***(þþ) 0.47
Sustained attention
(CPT-II)b
Commission errors (PR) 20 65 3–89 26 18 1–94 156.0 0.01** 0.34
Omission errors (PR) 20 38 21–99 26 36 20–96 244.0 0.36 0.27
Divided attention (TAP)a Commission errors (PR) 17 22 2–100 27 79 4–100 322.0 0.03* 0.34
Omission errors (PR) 17 29 1–100 27 46 1–96 293.5 0.12 0.05
Significance level: *P< 0.05; **P< 0.01; ***P¼<0.001 (uncorrected); (þ¼P< 0.05;þþ¼P< 0.01 after Holm–Bonferroni-Correction). aHigh
values indicate good performance. bLow values indicate good performance. cMann–Whitney U-test. PR, percentile rank.
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reported an accuracy variable in a single test [e.g., 17] rather than
examining different attentional variables derived from two
different attentional measures. Secondly, the inattentiveness
findings are based on data from BT patients gathered after
undergoing predominantly multiple cancer treatments rather than
at the time of initial diagnosis. Increased impulsivity might be a
result of disturbed networks by expansion of the tumor or tumor-
related transmitter imbalance that affect the limbic system which
then leads to changes in arousal, possibly reflected in increased
impulsivity measures.
Despite the attentional and mnemonic deficits of children with
BT, there was no significant difference between the two patient
groups in general intelligence this early in the course of treatment.
Mean IQs of patients with BT lie within the normal range, thus
confirming the results of Iuvone and colleagues.[17] Nevertheless,
deficits in memory and attention as early as the time of diagnosis
might make patients even more vulnerable to the damaging effects
of the medical treatments to follow.[18,33] Since attention and
learning processes are crucial for thriving in academic and social
skills,[34,35] impairment in these functions at an early stage will
put the patients at risk to fall behind same-aged peers. These deficits
will further be aggravated by chemo- and radiation therapy.
[33,36,37]
From a neuroanatomical point of view, these results are not
unexpected: In contrast to other cognitive functions, memory and
attention are based on the integrity of widely distributed neural
networks and are therefore prone to be affected by nearly any tumor
location and histology[38,39] as well as by intracranial high pressure
due to tumor-related hydrocephalus prior to diagnosis. The impact of
the localization of the damage seems to have only a limited impact on
the neuropsychological outcome.[40] Disturbing connectivity in a
developing system could have considerable impact on the develop-
ment of cognitive abilities.[41] For example,memory problems have
been documented in children treated for medulloblastoma,[42] or
craniopharyngeoma[43] and in children with third[44] and fourth
ventricle tumors[37] unlike patients treated for other tumors not
involving the CNS or healthy siblings.[45]
Twenty percent of the children with BT in our sample showed
impaired performance (<1SD) in at least four different cognitive
tests compared to only 4% of the children in the sample without
CNS involvement. Whereas in the first group impairment could
mainly be explained by compromised connectivity in the brain, in
the group without CNS involvement different cancer-induced
mechanisms like immunologic processes may be responsible for a
reduced cognitive performance.[46] Although there is a lack of
research into long-term neurocognitive outcomes of children with
BT, given their performance at diagnosis, it seems obvious that
preexisting deficits in basal functions will likely impair further
normal development of complex cognitive abilities.[47]
Emotion regulation is a process that demands a high amount of
resources[48,49] and accordingly can adversely affect processing
cognitive functioning if not successfully accomplished. In our two
patient groups, the children themselves and their parents respectively
rated their emotional distress, their social and behavioral difficulties
and their quality of life quite similarly. It seems that children with
BTs and children with other oncological diseases as well as their
families were exposed to a comparable level of emotional and
physical distress at diagnosis. Thus, the influence of anxiety, fear, and
general distress on the performance in the neuropsychological
assessment is likely comparable in both groups.
The generalizability of the present findings is limited in several
aspects. The primary limitation of the report is the relatively small
number of subjects. The small sample did not allow us to analyze in
detail different specific variables potentially influencing memory
and attention problems such as tumor histology, number and
duration of neurological symptoms, presentation of hydrocephalus
or epileptic seizures. Two studies with larger sample sizes[16,17]
indicate that several medical factors might relate to cognitive
problems in children with BT before surgery: histology and size of
the tumor, age at onset, brain stem infiltration, presence of
neurological deficits, longer symptom duration, hydrocephalus, and
epileptic seizures.
Nevertheless, what stands out in this work is the comparison of
cognitive performance in BT patients with that of children with non-
CNSmalignancies. Although our patient samples are heterogeneous,
the results can be highly informative. In the event of a brain tumor,
connectivity is interrupted and compromised. This is not the case in
patients with oncological illnesses outside the CNS. This disturbance
of connectivity could have considerable impact on further cognitive
development.[41] The present findings emphasize the significance of
and the high need for cognitive rehabilitation programs for children
with BT [e.g., 36] to minimize or even prevent long-term cognitive
impairment and to improve quality of life. Rehabilitation programs
ought to start as early as possible during the treatment process, as
soon as physical well-being and medical treatment allow. Thus,
cognitive training programs targeting memory and attention should
become part of the standard multi-disciplinary treatment of children
with brain tumors.
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